tiprankstipranks
Advertisement
Advertisement
Halozyme price target lowered to $93 from $96 at Morgan Stanley
PremiumThe FlyHalozyme price target lowered to $93 from $96 at Morgan Stanley
3M ago
Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
Premium
Ratings
Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
3M ago
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
Premium
Ratings
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
3M ago
Halozyme announces global collaboration and license agreement with GSK
PremiumThe FlyHalozyme announces global collaboration and license agreement with GSK
3M ago
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
Premium
The Fly
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
3M ago
Halozyme names Darren Snellgrove as CFO
Premium
The Fly
Halozyme names Darren Snellgrove as CFO
3M ago
Halozyme enters global global collaboration and license agreement with Vertex
PremiumThe FlyHalozyme enters global global collaboration and license agreement with Vertex
4M ago
Halozyme Names David Ramsay Interim Chief Financial Officer
Premium
Company Announcements
Halozyme Names David Ramsay Interim Chief Financial Officer
5M ago
Halozyme names David Ramsay as Interim CFO
Premium
The Fly
Halozyme names David Ramsay as Interim CFO
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100